跳至主要内容
临床试验/NCT06141941
NCT06141941
已完成
不适用

Does the Use of Continuous Glucose Monitoring (CGM) in the Immediate Postpartum Period in Women With Pregestational Diabetes Admitted to the Hospital Decrease Hypoglycemic Episodes

University of Iowa2 个研究点 分布在 1 个国家目标入组 39 人2021年6月1日
干预措施CGM

概览

阶段
不适用
干预措施
CGM
疾病 / 适应症
Pregestational Diabetes
发起方
University of Iowa
入组人数
39
试验地点
2
主要终点
Glucose values
状态
已完成
最后更新
23天前

概览

简要总结

This study will examine whether continuous glucose monitoring in patients hospitalized in the immediate postpartum period is more effective than traditional point of care glucose testing in identifying patients with hypoglycemia.

详细描述

This is a prospective cohort study of women with type 1 and type 2 diabetes in the postpartum period. After obtaining informed consent, a CGM device (Dexcom sensor and transmitter) will be placed by research personnel upon presentation to labor or in prenatal clinic if seen within 3 days of planned induction of labor or planned cesarean section. Patient will be assisted in getting the Dexcom G6 app on their cell phone to be the receiver of glucose data. Patients who are currently using the Dexcom CGM for routine monitoring of their glucoses, will be allowed to continue using their own sensor and transmitter. Upon presentation to Labor and Delivery, patients will be assisted in activating the Share App on their cell phone. Labor and Delivery Nursing Staff will be given a Samsun phone with the Follow app in order to receive glucose data. The Samsung phone will be transferred to the Mother/Baby Unit with the patient after delivery. Glucose values from the CGM device will then be available to nursing through the Samsung phone. Nursing will be able to see current glucose data on their patient and would receive alarms to indicate hypoglycemia or impending hypoglycemia. Nursing will be provided with instructions for how to access the CGM follow app and how to appropriately respond to the alarms. Nursing will continue to perform standard of care blood glucose monitoring per routine protocol but will also obtain a finger stick to validate a blood glucose level whenever a low CGM alarm sounds. Low blood glucose values \<70 mg/dl will be treated per local institutional nursing policy. Monitoring of glucose levels through the CGM device will continue throughout their postpartum hospital stay. This is typically 2 days for a vaginal delivery, 3 days for a cesarean section. Patients who do not use CGM as part of their routine care, will have their CGM sensor and transmitter removed prior to discharge from the hospital. Following discharge from the hospital, there will be no additional long term follow-up. Data we plan to collect for analysis includes: type of diabetes (DM1/DM2), point of care glucose values, number of hypoglycemic events, number of times treated for hypoglycemia.

注册库
clinicaltrials.gov
开始日期
2021年6月1日
结束日期
2024年4月30日
最后更新
23天前
研究类型
Interventional
研究设计
Single Group
性别
Female

研究者

责任方
Sponsor
主要研究者

Andrea L. Greiner

Clinical Professor

University of Iowa

入排标准

入选标准

  • 1- Individuals in the third trimester of pregnancy admitted to the hospital with diabetes type 1 or diabetes type 2, own a smart device (which will serve as a receiver for the CGM device)

排除标准

  • Patients less than 18 years of age
  • non-English speaking patients
  • gestational diabetes
  • extensive skin changes/diseases that inhibit wearing a sensor on normal skin, known allergy to adhesives

研究组 & 干预措施

CGM

A CGM device (Dexcom sensor and transmitter) will be placed by research personnel upon presentation to Labor and Delivery unit.

干预措施: CGM

Standard glucometer

干预措施: CGM

结局指标

主要结局

Glucose values

时间窗: Postpartum admission, 2-4 days

glucose values obtained from CGM application

Number of Participants With Hypoglycemia During Postpartum Hospital Stay

时间窗: Postpartum admission, 2-5 days

glucose values

研究点 (2)

Loading locations...

相似试验